Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PCS CAN CONTINUE TO USE RESTRICTED FORMULARIES UNDER FTC CONSENT AGREEMENT; LILLY AGREES TO OFFER OPEN FORMULARIES TO ALL CLIENTS, MAINTAIN P&T COMMITTEE

Executive Summary

PCS can provide any type of open or closed formulary that a client requests -- as long as PCS abides by a Federal Trade Commission order to let payers know that a PCS open formulary is an option.

You may also be interested in...



FTC Review Of Caremark Deal Will Be Fourth Look At PCS

FTC's review of the Caremark/AdvancePCS merger will be the agency's fourth look at the PCS pharmacy benefit management business in less than a decade - but the first time the agency has considered a straightforward horizontal merger among independent, stand-alone PBMs

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

Latest Headlines
See All
UsernamePublicRestriction

Register

PS025262

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel